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INTRODUCTION 
 Acquired Immuno Deficiency Syndrome was first recognized in the 
United States in 1981 when the U.S Center for Disease Control and 
prevention (CDC) reported unexplained occurrence of Pneumocystis 
jiroveci pneumonia in five previously healthy homosexual men. Within 
months, disease was recognized in injection drug users (IDUs), in recipient 
of blood transfusions and hemophiliacs.1 
 In 1983, Human Immuno Deficiency Virus was isolated from a 
patient with lymphadenopathy and in 1984 it was demonstrated clearly to 
be the causative agent of AIDS. 1 India's first case of AIDS was reported in 
1986 from Chennai.2 
 From the beginning of the AIDS epidemic, it was recognized first at 
autopsy and later by non invasive techniques that HIV infection can cause 
cardiac abnormalities. The prevalence of cardiac disease in HIV infected 
individuals is not clear; the reported frequency of cardiac abnormalities 
depends on the population studied and the definition of cardiac 
abnormality. 
Before the advent of Anti-retroviral therapy (ART), clinically 
significant cardiac disease was universal in the HIV infected population 
and was detected in most cases only at autopsy. However cardiac 
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abnormalities in AIDS patients appears to be more common than 
previously thought. In fact when HIV infected patients were examined by 
echocardiography in late 1990, cardiac abnormalities were detected more 
often than could be expected from clinical symptoms and physical 
examination. Although most conditions are clinically quiescent, some may 
have devastating and fatal outcomes. Pericardial effusion and Myocarditis 
are among the most commonly reported abnormalities though 
cardiomyopathy, endocarditis and coronary vasculopathy have also been 
reported. 
 It is expected that the risk of cardiac and cardiovascular disease will 
rise in the following years due to the cardiovascular risk profile and 
increased life expectancy of infected patients. Therefore diagnosis and 
therapy of HIV associated cardiovascular diseases should be an inherent 
part of current therapeutic concepts of HIV infection.   
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         AIM OF THE STUDY 
 
1. To study the prevalence of cardiac abnormalities in HIV infected 
individuals. 
2. To correlate the cardiac abnormalities with CD4 cell count. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
GLOBAL SCENERIO OF HIV 3     
z An estimated 33 million people [30.3 – 36.1 million] were living 
with HIV in 2007.  
z There were 2.7 million [2.2 – 3.2 million] new HIV infections and        
2 million [1.8 – 2.3 million] AIDS-related deaths last year. 
z The rate of new HIV infections has fallen in several countries, but 
globally these favourable trends are atleast partially offset by 
increases in new infections in other countries. 
z Sub-Saharan Africa has two thirds (67%) of all people living with 
HIV worldwide. 
z Globally, women account for half of all HIV infections—               
this percentage has remained stable for the past several years. 
z An estimated 370000 [330000 – 410000] children (younger than 15 
years) became infected with HIV in 2007.  
z The total number of children living with HIV has increased from  
1.6 million [1.4 – 2.1 million] in 2001 to 2 million [1.9 – 2.3 
million] in 2007 - almost 90% live in sub-Saharan Africa. 
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INDIAN SCENERIO OF HIV 4 
z An estimated 2.47 million (2 - 3 million) peoples were living with 
HIV / AIDS  
z HIV prevalence among people 15 to 49 years of age was 0.28% 
(0.23 - 0.33%) 
z Prevalence of HIV in adults was 0.36%. 
z Highest prevalence was found among people 30 to 34 years old – 
0.64% among men and 0.45% among women. 
z Prevalence was higher in urban areas than in rural areas. 
z Prevalence was higher among male than female in all age groups 
except those 15 to 19 years of age, in which rates were very low. 
z HIV prevalence was stable or declining among pregnant women in 
the high prevalence states of Andhra Pradesh, Karnataka and              
Tamil Nadu. 
z HIV transmission is primarily sexual, except in northeastern India 
where there is high rate of spread through injection-drug use. 
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SCENERIO IN TAMILNADU 5 
z HIV prevalence in different population are as follows 
Antenatal clinic attendees – 0.25%  
STD clinic attendees – 8% 
Female sex workers – 4.62% 
Men having sex with men – 5.60% 
Intra venous drug users – 24.2% 
District Categorization 5 
z Category A: More than 1% ANC prevalence in district in any of the 
sites in the last 3 years.  
z Category B: Less than 1% ANC prevalence in all the sites during         
last 3 years with more than 5% prevalence in any HRG site 
(STD/FSW/MSM/IDU).  
z Category C: Less than 1% ANC prevalence in all sites during last 3 
years with less than 5% in all HRG sites, with known hot spots 
(Migrants, truckers, large aggregation of factory workers, tourist 
etc).  
7 
 
z Category D: Less than 1% ANC prevalence in all sites during last  
3 years with less than 5% in all HRG sites with no known hot spots 
and no or poor HIV data.  
z In Tamil Nadu, among 30 districts, 22 districts are in category A,               
5 districts are in category B and 3 districts are in category C. 
HUMAN IMMUNODEFICIENCY VIRUS 1 
 The origin of HIV is unclear. The most likely scenario is that HIV 
was introduced into human from another primate in Sub-Saharan Africa. 
ETIOLOGIC AGENT 1  
 The etiologic agent of AIDS is Human Immuno Deficiency Virus 
(HIV) which belongs to the family of human retroviruses (Retroviridae) 
and the sub families of lentiviruses.There are two sub types of HIV namely 
HIV-1 and HIV 2.They are cytopathic viruses. HIV-2 is more similar to 
SIV (Simian Immuno Deficiency Virus) than HIV-1 and it is much less 
virulent usually not resulting in full blown AIDS, but still fatal. 
MORPHOLOGY OF HIV 1 
 Electron microscopy shows that the HIV is spherical enveloped 
virus, about 90 - 120 nm in size. The nucleocapsid has an outer icosahedral 
shell containing numerous external spikes formed by the two major 
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envelope proteins, the external gp 120 and the transmembrane gp 41.     
The core virus particle is composed of ribonucleoproteins. 
HIV GENOME 1 
 HIV-1 has the following genes. gag – encodes the proteins that form 
the core of virion. pol – encodes viral enzymes necessary for replication, 
reverse transcriptase, integrase and protease and env – encodes 
glycoprotein. It also contains atleast six other genes tat, rev, nef, vpr, vpu 
which code for proteins involved in the regulation of gene expression.   
The major difference between the genomes of HIV-1 and HIV-2 is the fact 
that HIV-2 lacks the vpu gene and has vpx gene not contained in HIV-1. 
LIFE CYCLE 1 
ATTACHMENT AND ENTRY  
 The replication cycle of HIV begins with the high affinity binding of 
the gp 120 protein via a portion of its V1region near the N terminus to its 
receptor on the host cell surface, the CD4 molecule. It is also expressed on 
the surface of monocytes and dendrites / langerhans cells. Once gp 120 
binds to CD4, the gp 120 undergoes a conformational change that 
facilitates binding to one of a group of co-receptors. The two major        
co-receptors are CCR5 and CXCR4. 
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REVERSE TRANSCRIPTION AND INTEGRATION 
 Following binding of the envelop protein to the CD4 molecule,      
the virus is “uncoated” and the viral RNA is converted into complementary 
DNA (C-DNA) by virion associated reverse transcriptase enzyme.            
The C-DNA is transported to the host cell nucleus and eventually gets 
incorporated into the host cell chromosomes by virus specific integrase 
enzyme. 
TRANSCRIPTION, TRANSLATION AND REPLICATION 
 The integrated DNA is transcribed into messenger RNA (mRNA) 
which comes out into cytoplasm and viral proteins are synthesized using 
protein synthesizing machinery and raw material from the host cell. Some 
of the viral proteins are synthesized as polyproteins that are eventually 
cleared by the proteinase enzyme. 
MATURATION AND RELEASE 
 Newly synthesized progeny RNA and proteins are packaged 
together and the newly formed virus particles are released from the 
infected cell by the budding process. 
10 
 
PROGRESSION OF ILLNESS 1 
 The median time from primary HIV infection to the development of 
AIDS in untreated individuals is approximately 10 years. Individuals are 
considered to be long term survivors if they remain alive for ≥ 20 years 
after initial infection. It may be related to beneficial effect of ART and 
prophylaxis against opportunistic infections. Long term nonprogressors are 
those who have been infected with HIV for ≥ 10 years whose CD4 count 
are in the normal range and remained stable over years and who had not 
received ART.   
The reasons being 
1. Mutant nef gene of HIV 
2. Heterozygosity for CCR5- ∆32 deletion 
3. Heterozygosity for CCR2-64I mutation 
4. Homozygosity for SDF1-3’A mutation  
5.  Heterozygosity for the RANTES-28G mutation  
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CLASSIFICATION 1 
1993 Revised classification system for HIV infection and expanded AIDS  
surveillance case definition  for adolescents and adults 
Table 1 
A B C
Asymptomatic, 
Acute (primary) 
HIV or PGL
Symptomatic, 
Not A or C 
Conditions
AIDS- 
Indicator 
Conditions
≥ 500 /µl A1 B1 C1
200 - 499 /µl A2 B2 C2
< 200/ µl A3 B3 C3
Clinical categories
CD4+ T cell  
Categories
 
PGL – Progressive Generalized Lymphadenopathy 
HIV infected persons classified in A3, B3, C1, C2 and C3 are AIDS cases 
Category A: 
 One or more of the following conditions in adolescents or adults    
(> 13 years) with documented HIV infection. 
Conditions listed in categories B and C must not have occurred. 
1. Asymptomatic HIV infection 
2. Progressive Generalized Lymphadenopathy 
3. Acute (primary) HIV infection with accompanying  illness or history 
of acute HIV infection 
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Category B: 
 Consists of symptomatic conditions in an HIV infected adolescent or 
adult that are not included among conditions listed in clinical category C 
and that meets one of the following criteria 
1. The conditions are attributed to HIV infection or are indicative of a 
defect in cell mediated immunity (CMI). 
2. Conditions are considered by physicians to have a clinical course or 
to require management that is complicated by HIV infection. 
Examples include, but are not limited to the following. 
a. Bacillary angiomatosis 
b. Candidiasis, oropharyngeal (thrush) 
c. Candidiasis, vulvovaginal: persistent, frequent or poorly responsive 
to therapy 
d. Cervical dysplasia (moderate or severe) / cervical carcinoma in situ 
e. Constitutional symptoms, fever or diarrhea lasting > 1 month 
f. Oral hairy leukoplakia 
g. Herpes zoster involving atleast 2 distinct episodes or more than one 
dermatome 
h. Idiopathic thrombocytopenic purpura 
i. Listeriosis 
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j. Pelvic inflammatory disease, particularly complicated by 
tuboovarian abscess 
k. Peripheral neuropathy 
Category C: 
Conditions listed in AIDS surveillance case definition 
a. Candidiasis of  bronchi, trachea or lungs 
b. Candidiasis, esophageal 
c. Cervical cancer, invasive 
d. Coccidioidomycosis, disseminated or extrapulmonary 
e. Cryptococcosis, extrapulmonary 
f. Cryptosporidiosis, chronic intestinal (> 1 month’s  duration) 
g. Cytomegalovirus disease (other than liver, spleen or nodes) 
h. Cytomegalovirus retinitis (with loss of vision) 
i. Encephalopathy, HIV related 
j. Herpes simplex: chronic ulcers (> 1 month’s  duration) or bronchitis, 
pneumonia or esophagitis 
k. Histoplasmosis, disseminated or extra pulmonary 
l. Isosporiasis, chronic intestinal (> 1 month’s  duration)  
m. Kaposi’s sarcoma 
n. Lymphoma, Burkitt’s (or equivalent term) 
o. Lymphoma, primary of  brain 
p. Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary 
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q. Mycobacterium tuberculosis, any site (pulmonary or 
extrapulmonary) 
r. Mycobacterium, other species or unidentified species, disseminated 
s. or extrapulmonary 
t. Pneumocystis jiroveci pneumonia 
u. Pneumonia, recurrent 
v. Progressive multifocal leukoencephalopathy 
w. Salmonella septicemia, recurrent 
x. Toxoplasmosis of  brain 
y. Wasting syndrome due to HIV 
CLASSIFICATION OF HIV INFECTION (WHO CLINICAL 
STAGING SYSTEM) 7 
Clinical stage 1: 
a. Asymptomatic  
b. Persistent Generalized Lymphadenopathy 
Clinical stage 2: 
a. Weight loss <10% of body weight 
b. Recurrent upper respiratory tract infections (e.g. bacterial sinusitis) 
c. Herpes zoster 
d. Angular cheilitis 
e. Recurrent oral ulceration 
f. Papular pruritic eruptions 
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g. Seborrhoeic dermatitis 
h. Fungal nail infections 
Clinical stage 3: 
a. Weight loss > 10% of body weight 
b. Unexplained chronic diarrhea > 1 month 
c. Unexplained persistent fever (intermittent or constant) > 1 month 
d. Persistent Oral Candidiasis (thrush) 
e. Oral hairy leukoplakia 
f. Pulmonary tuberculosis 
g. Severe bacterial infections (e.g. pneumonia, pyomyositis) 
h. Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
i. Unexplained anemia (< 8 g / dl), neutropenia (< 0.5 X 109 / litre) and 
or chronic thrombocytopenia 
Clinical stage 4: 
a. HIV wasting syndrome 
b. Pneumocystis jiroveci pneumonia 
c. Recurrent severe bacterial pneumonia 
d. Toxoplasmosis of the brain 
e. Chronic Cryptosporidiosis 
f. Chronic Isosporiasis 
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g. Cryptococcosis - extrapulmonary 
h. Cytomegalovirus infection (retinitis or infection of other organs) 
i. HIV Encephalopathy 
j. Chronic Herpes simplex infection  (orolabial, genital or anorectal of       
> 1 month’s duration or visceral at any site) 
k. Disseminated endemic mycosis (Extrapulmonary Histoplasmosis, 
Coccidiomycosis) 
l. Kaposi’s sarcoma 
m. Candidiasis - esophagus, trachea, bronchi or lungs 
n. Disseminated non-tuberculous  mycobacteria infection 
o. Mycobacterium tuberculosis, extrapulmonary 
p. Progressive multifocal leukoencephalopathy 
q. Recurrent septicemia (including non typhoid salmonella septicemia) 
r. Lymphoma (Cerebral or B cell Non-Hodgkin) 
s. Invasive cervical carcinoma 
t. Atypical disseminated leishmaniasis  
u. Symptomatic HIV-associated nephropathy or symptomatic HIV 
associated cardiomyopathy 
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WHO CASE DEFINITION FOR AIDS SURVEILLANCE IN ADULT 
WHERE HIV TESTING FACILITIES NOT AVAILABLE 7 
 Case definition for AIDS is fulfilled if at least two major signs and 
one minor sign are present 
 
Major signs: 
a. Weight loss > 10% of  body weight 
b. Chronic diarrhea > 1 month 
c. Prolonged fever  > 1 month 
 
Minor signs: 
a. Persistent cough > 1 month 
b. History of herpes zoster 
c. Oropharyngeal candidiasis 
d. Generalized lymphadenopathy 
e. Chronic progressive herpes simplex infection 
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WHO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS 7 
Table 2 
Classification of HIV associated 
clinical disease
WHO 
clinical 
stage
CD4 test not 
available or 
pending
CD4 test available
Asymptomatic 1 Do not treat
Mild symptoms 2 Do not treat
Advanced symptoms 3 Treat
Consider treatment if 
CD4 <350 and initiate 
ART before CD4 drops 
below 200
Severe / Advanced symptoms 4 Treat Treat irrespective of CD4 count
Treat if CD4count <200
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NACO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS 6 
Table 3 
CD4 count    (cell 
/mm3)
Actions
< 200 Treat irrespective of clinical stage   
200 – 350 
. Offer ART for symptomatic patients                               
. Initiate treatment before CD4 drop below 200 
cells/mm3 for  asymptomatic people *
>350 Defer treatment in asymptomatic persons
 
* If CD4 count is between 200- 250, this should be repeated in four 
weeks and treatment to be considered in asymptomatic patients. 
British HIV association (BHIVA) suggests initiation of  ART for 
asymptomatic HIV infected individuals having less than 200 CD4 T cell 
counts.70 International AIDS society recommends initiation of ART in 
asymptomatic individuals with CD4 count > 200 to 350 cells / µl and viral 
load 50000 - 100000 copies / ml.71  
  In a study by Ramalingam et al, conducted in 2001 have shown 
that  mean CD4 counts in south Indian population both normal and HIV 
infected individuals are lower than in western population and have 
proposed a modified classification based on CD4 cell count for south 
Indians. The categories of CD4 count proposed were cell count   > 300,   
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81 - 300, ≤ 80 cells / µL, instead of the ≥ 500, 201-499, ≤ 200 
recommended by CDC(Centre for Disease Control and prevention).72 
              Kannagai et al study conducted in 2008 has shown that majority 
of HIV infected individuals in South India with CD4 counts of 200 - 350 
cells / µL had higher viral load than that suggested by International AIDS 
Society.57 
CARDIAC MANIFESTATIONS IN HIV INFECTED INDIVIDUALS 
The reasons for the paucity of knowledge about the etiology of HIV 
associated cardiovascular diseases are  
1. In the early years of AIDS epidemic, most patients died of infectious 
complications, before the manifestations of cardiovascular 
complications. 
2. Because cardiomyocytes do not have CD4 receptors, the heart was 
thought to be unaffected by HIV infection. 
3. Presence of cardiovascular risk factors like poor nutrition, alcohol 
and drugs that can lead on to cardiac disease in HIV infected 
individuals. 
4. Cardiac disease remains relatively asymptomatic in early stages of 
HIV infection. 
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5. Heart disease can be overlooked in HIV-positive patients, because 
symptoms of breathlessness, fatigue and poor exercise intolerance 
are frequently ascribed to other conditions associated with HIV 
infection. 
Some form of heart disease is demonstrable at autopsy in 
approximately 40% of cases and by echocardiography in 25% of patients 
with AIDS. Many of these lesions are mild, and HIV related heart disease 
probably causes symptoms in less than 10% and death in less than 2% of 
all patients with HIV infection.8 
 At the beginning of the epidemic, heart muscle disease was the 
dominant cardiac complication of HIV infection in developed world, and 
tuberculous pericarditis in Africa. The advent of HAART (highly active 
anti-retroviral therapy) has changed the pattern of disease in developed 
countries where premature coronary artery disease and other 
manifestations of atherosclerosis are now the most common cardiovascular 
disorder. This is partly caused by HAART-induced metabolic problems, 
particularly insulin resistance and hyperlipidemia, but also reflects a high 
prevalence of conventional risk factors such as smoking.8  
 Cardiac problems associated with advanced immunodeficiency, such 
as heart muscle disease, pericardial effusion and pulmonary hypertension 
continue to predominate in resource-poor countries where less than 5% of 
patients are able to access anti-retroviral drugs.8  
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CARDIAC MANIFESTATIONS OF HIV/AIDS 8 
Table 4 
Pericardial effusion   
. Idiopathic                                                    . 
Infections (viral, bacterial and fungal)                  
. Neoplastic (Kaposi's sarcoma and          Non 
Hodgkins Lymphoma)           
 Heart muscle disease
. Myocarditis (idiopathic / lymphocytic, 
infections, toxins)                                                 
. Dilated cardiomyopathy & Left Ventricular 
dysfunction      
Endocarditis 
. Marantic (nonbacterial thrombotic 
endocarditis)                                                        
. Infective                                                             
Tumors 
. Kaposi's sarcoma                                               
. Lymphoma
Right ventricular dysfunction & 
Pulmonary hypertension
. Primary                                                              
. Secondary (recurrent chest infections, 
thromboembolism)                           
Premature atherosclerosis and 
Coronary artery disease
. Protease inhibitors, chronic inflammation, 
Autonomic dysfunction
. CNS disease, drugs, prolonged 
immunodeficiency, malnutrition                           
Arrythmias  
. Drugs, autonomic dysfunction, acidosis, 
electrolyte abnormalities
Vasculitis . Antibiotics and antivirals
Adverse drug effects                   
. Hyperlipidemia                                                  
. Proarrythmia
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CARDIOVASCULAR ASSESMENT OF THE HIV/AIDS PATIENT 
 Heart disease can be overlooked in HIV-positive patients, because 
symptoms of breathlessness, fatigue and poor exercise intolerance are 
frequently ascribed to other conditions associated with HIV infection.9 
Echocardiographic assessment of HIV patients is extremely useful and can 
be used to identify those cardiac conditions that can be associated with 
poor outcome: pericardial effusion,10 left ventricular (LV) systolic 
dysfunction / heart muscle disease,9 intracardiac masses.11 
INDICATIONS FOR ECHOCARDIOGRAPHIC ASSESSMENT OF 
HIV POSITIVE PATIENTS 8 
1) Possible baseline assessment at the time of diagnosis of HIV 
infection 
2) Base line assessment and 1 - 2 yearly monitoring of patient with 
i) Clinical manifestations of possible cardiac involvement 
z Unexplained dyspnea / hypoxia 
z Third heart sound, inappropriate tachycardia 
z Raised jugular venous pressure 
z Peripheral edema / right heart failure 
z Radiographic evidence of cardiomegaly 
ii) viral coinfection 
z Cytomegalovirus 
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z Epstein-Barr virus 
z Coxsackie virus 
z Adeno virus 
iii) History of preexisting cardiac disease 
z Left ventricular systolic dysfunction (any cause) 
z Valvular heart disease 
z Suspicion of infective endocarditis in intravenous drug 
users 
iv) High-risk HIV patients with: 
z Wasting 
z Encephalopathy 
z CD4 count < 100 cells / mm3 or AIDS 
z Potentially cardiotoxic medications 
z Multiple hospitalizations 
   3) Possible 1-2 yearly monitoring of asymptomatic HIV positive patients 
  4) Frequent assessment of HIV positive patients with cardiovascular        
 involvement (as guided by cardiologist) 
HIV/AIDS AND THE PERICARDIUM  
 Pericardial effusion and pericarditis are the most common 
abnormalities found in early HIV/AIDS autopsy studies. Effusions are 
generally small and asymptomatic. 
25 
 
Pericardial effusion may be related to an opportunistic infection, metabolic 
abnormality or malignancy, but most often a clear etiology is not found.        
The effusion is often part of a generalized serous effusive process also 
involving pleural and peritoneal surfaces. This capillary leak syndrome 
may be related to enhanced cytokine production in the later stages of HIV 
disease. Other causes can include uremia from HIV-associated 
nephropathy.12 Effusion markedly increases the mortality. 
Screening echocardiography is recommended for HIV-infected 
individuals regardless of  the stage of the disease.13 Patients should 
undergo pericardiocentesis if they have pericardial effusion and clinical 
signs (elevated jugular venous pressure, dyspnea, hypotension, persistent 
tachycardia, pulsus paradoxus) or  Echocardiographic signs of tamponade 
(Continuous Wave Doppler evidence of respiratory variation in valvular 
flow, septal bounce, right ventricular collapse, a large effusion).14 
Patients with pericardial effusion without tamponade should be 
evaluated for treatable opportunistic infections, such as tuberculosis and 
for malignancy. Repeated echocardiography is recommended after one 
month or sooner if clinical symptoms direct.14 
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HIV/AIDS AND THE MYOCARDIUM  
MYOCARDITIS 
Numerous pathologic studies have confirmed the presence of 
varying histologic patterns of lymphocytic myocarditis in HIV patients.15 
As such, estimates of the prevalence of myocarditis in HIV/AIDS varies 
from 53% 16 in the pre-HAART era to much lower levels today in the 
developed world.17 
There are several hypotheses regarding the etiology of myocarditis 
in AIDS including:  
1) Primary HIV myocarditis  
2) Secondary HIV myocarditis 
3) Opportunistic infections 
4) Autoimmunity 
1) Primary HIV Infection of the Myocardium 
HIV neither has been universally accepted nor unambiguously 
proven causative agent of myocarditis in AIDS. 
Although HIV can clearly infect monocytes/macrophages and 
myocardial interstitial cells, evidence proving that HIV can infect human 
cardiac myocytes which do not possess CD4 receptor is less clear.8            
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HIV gene sequences have been detected by PCR in microdissected 
endomyocardial biopsies from HIV-positive patients some of whom had 
cardiac symptoms.18 HIV has also been shown gain entry into human fetal 
cardiac myocyte by ingestion through a specific crystallizable fragment (of 
immunoglobulin) (Fc) receptor, and it remains possible that this or other, 
unidentified mechanisms can promote HIV entry into the myocyte and 
facilitate a primary HIV myocarditis.19 
2) Secondary HIV Myocarditis 
Interstitial lymphocytes and macrophages can form contact with 
myocytes causing focal loss of  basement membrane through a local 
reaction.20 Proteolytic enzymes released through HIV replication in the 
interstitium could also damage myocytes.21 The HIV envelope 
glycoprotein group 120 can induce tumor necrosis factor-α  (TNF-α) 
expression from macrophages and has been shown to enhance IL-1induced 
nitric oxide production in neonatal rat cardiac myocytes.22 Cytokine IL-6 
which has some effect on immune response and viral replication  in murine 
myocarditis, has been found in excess in small number of  HIV-positive 
patients with biopsy proven myocarditis.23 
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3) Myocardial Opportunistic Infections in HIV/AIDS 
 Autopsy has confirmed a variety of opportunistic infections of the 
myocardium in patients with AIDS. Infectious agents included 
Toxoplasma gondii, Cryptococcus, cytomegalovirus, Candida, 
Pneumocystis jiroveci, Microsporidium, Histoplama capsulatum, Atypical 
mycobacteria and Aspergillus organisms involving the myocardium.8 
4) Autoimmunity 
 Many autoimmune processes have been described in association 
with HIV/AIDS infection. HIV infection can itself trigger autoimmune 
phenomenon in susceptible patients.24 The presence of auto antibodies 
along with hypergammaglobulinemia and elevated circulating immune 
complexes suggests that yet unidentified autoimmune process can take 
place in HIV positive patients.25 
The symptoms of myocarditis are protean and include fatigue, 
dyspnea and pleuritic chest pain. The signs are unexplained tachycardia, 
third heart sound or a friction rub. ECG may show nonspecific conduction 
defects, repolarization abnormalities and ST-T wave changes, although 
these are not invariable. Chest radiograph can be normal or suggest cardiac 
enlargement with pulmonary congestion. Echocardiography is usually non 
diagnostic but can show hyperdynamic LV function in HIV-positive 
children or occasionally LV dyskinesia in adult AIDS patients.8
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DILATED CARDIOMYOPATHY AND LEFT VENTRICULAR  
DYSFUNCTION IN HIV/AIDS 
 The prevalence of heart muscle disease appears to be approximately 
4.4% for dilated cardiomyopathy and 6.4% for isolated LV dysfunction 
and the condition can cause symptoms in up to 5.5% of HIV/AIDS 
patients.9 The presence of dilated cardiomyopathy is ominous and 
associated with poor survival compared to patients with structurally 
normal hearts. This poor outlook remained true even after correcting CD4 
counts. 
Mechanisms of Cardiomyopathy in HIV/AIDS 
The mechanisms for the development of LV dysfunction, 
cardiomyopathy in AIDS remain unclear. In addition to the role of  HIV, 
lymphocytic myocarditis, cytokines and  autoimmune responses, the 
contributions of  illicit and prescribed medications, nutritional deficiencies 
and other factors also appears to be pathogenetically or 
pathophysiologically important.15 
Drug Induced Heart Muscle Disease 
 Zidovudine and other Nucleoside Reverse Transcriptase Inhibitors 
(NRTIs) can be implicated in the development of some cases of heart 
muscle disease. In addition to inhibiting HIV reverse transcriptase, the 
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drug causes a dose dependent reversible skeletal myopathy by altering 
mitochondrial DNA replication.26 Foscarnet in CMV infection associated 
with reversible congestive cardiac failure as has doxorubicin and 
interferon-α therapy in Kaposi’s sarcoma.8 
The effect of recreational drugs like cocaine use has been associated 
with myocarditis and a possibly reversible dilated cardiomyopathy in    
non-AIDS patients should be considered in the HIV population.27 
Nutritional Deficiencies and Cardiac Dysfunction in HIV/AIDS 
HIV/AIDS patients with evidence LV systolic dysfunction should be 
assessed for micro nutrient deficiency, which is common in HIV infected 
individuals. Abnormally low levels of selenium and antioxidants have been 
demonstrated and oxidative stress can be an important mechanism for 
cellular damage in AIDS.28 Selenium deficiency is implicated in the 
pathogenesis of Keshan disease, a specific form of dilated cardiomyopathy 
in China, which can respond to dietary supplementation. In the same way, 
decreased selenium content has been demonstrated in the hearts of AIDS 
patients.29 
L- Carnitine deficiency has also been described in HIV patients, 
possibly in association with cardiac symptoms and in whom 
supplementation can be advantageous. Experimentally, Carnitine 
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administration reversed myopathic changes induced by Zidovudine (AZT) 
in vitro, but the clinical effects have yet to be established.30 
The echocardiographic features of dilated cardiomyopathy is global 
LV systolic dysfunction with the consistent feature of reduced ejection 
fraction.31 LV dilatation can result in mitral valve distortion and lead to 
regurgitation.  In AIDS patients, mitral regurgitation has also been 
described with infective endocarditis.32 Abnormalities of mitral flow, 
specifically reduced early mitral peak velocity (E) and other indices of 
diastolic dysfunction have been noted early in the course of HIV/AIDS 
with normal ejection fraction and in association with LV systolic 
dysfunction.33 
No randomized trials have been reported regarding the effectiveness 
of current heart failure therapies in people with HIV/AIDS.9 Common 
agents such as diuretics, aldosterone antagonists, and digoxin can improve 
well being. Angiotensin inhibitors can be poorly tolerated, possibly 
because many patients already have low systemic vascular resistance.34 
Etarnacept, pentoxifylline have been used in severe heart failure with some 
success.35,36 
Intravenous immunoglobulin therapy has been used successfully in 
children with symptomatic HIV heart muscle disease and can be protective 
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against the development of LV dysfunction in that group.37 The use of 
cardiac resynchronization therapy has not been described in HIV 
population, although case reports of successful use of LV assist devices 38 
and orthotopic heart transplant39 exist, although these are uncommon.  
NONBACTERIAL THROMBOTIC ENDOCARDITIS 
Marantic or nonbacterial thrombotic endocarditis (NBTE) is a 
condition in which friable clumps of platelets and red cells adhere to the 
cardiac valves. Unlike bacterial endocarditis these lesions are not infective 
and show no evidence of an inflammatory reaction. 
The pathogenesis is not fully understood, but hypercoagulability, 
immune complex deposition, or specific vitamin deficiency can be 
important in conjunction with endothelial damage from intravenous 
catheters or injected particulate matters. Any heart valve can be affected 
and frequently multiple lesions are found on different levels.40 
Treatment should focus on reducing the underlying disease causing 
coagulation abnormalities, valvular endothelial damage or both. An 
anticoagulation risk benefit assessment must be made on individual basis.14 
INFECTIVE ENDOCARDITIS 
The immunological abnormalities associated with HIV render 
patients susceptible to bacterial infections. The clinical presentation is 
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same for both HIV positive and negative patients but runs a more 
fulminant course in later stages of AIDS.41 The most common valve 
involved is the tricuspid valve as with infective endocarditis in HIV 
negative intravenous drug users. Most frequently isolated organisms 
include staphylococcus aureus, salmonella species, streptococcus viridans 
but fungal endocarditis can occur in end-stage AIDS.14 Antimicrobial 
treatment may have to be widened. Operative indications include 
hemodynamic instability, failure to sterilize blood cultures after 
appropriate intravenous antibiotics and severe valvular destruction in 
patients with reasonable life expectancy after recovery from surgery.14 
CARDIAC TUMORS IN HIV/AIDS 
 Kaposi’s sarcoma (KS) is the most common AIDS related neoplasia; 
there is often widespread and potentially fatal visceral involvement in 
HIV- positive individuals. The prevalence of cardiac Kaposi’s sarcoma 
appears to have decreased significantly since early reports.34 
It's not usually associated with symptoms of  cardiac dysfunction; 
but cases of fatal tamponade associated with the tumor have been reported, 
and heart failure without ventricular dilatation can occur in cases with 
extensive myocardial infarction.8 Kaposi’s sarcoma can be treated with 
daunorubicin, doxorubicin or related anthracyclines. Liposomal 
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encapsulated daunorubicin has an improved pharmacological profile and 
can therefore be preferred in patients with Kaposi’s sarcoma and AIDS.42 
Non Hodgkin’s Lymphoma (NHL) can involve the pericardium or 
myocardium. Cardiac lymphoma commonly gives rise to clinical 
symptoms of tamponade, heart failure, and conduction abnormalities or 
superior vena cava syndrome. Systemic chemotherapy with or without 
concomitant radiation or surgery has been beneficial in some patients, but 
overall the prognosis is poor.8 
RIGHT VENTRICULAR DYSFUNCTION 
 Isolated right ventricular dysfunction without pulmonary 
hypertension is of unknown significance and can be related to changes in 
pulmonary circulation. Therefore bronchopulmonary infections should be 
treated aggressively and intravenous drug use, which can result in micro 
vascular pulmonary emboli should be discouraged.8 
PULMONARY HYPERTENSION 
 Primary pulmonary hypertension is estimated to occur in 0.5% of 
hospitalized AIDS patients.43,44 Although  pulmonary hypertension can be 
related to the action of viral proteins 45,46 or the action of cytokines on the 
endothelial cell, characteristic pulmonary arteriopathy is found in HIV-
related pulmonary hypertension. Right heart catheterization can be 
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worthwhile to determine if pulmonary hypertension can be reversed and 
has been used in HIV patients.47 HAART itself  can be beneficial in terms 
of  outcome in pulmonary hypertension 48 but agents like bosentan, 
epoprostenol,47 treprostinil 49 or sildenafil can improve feeling of well 
being without altering prognosis. 
ACCELERATED ATHEROSCLEROSIS 
 Accelerated atherosclerosis has been observed in young HIV-
infected adults and children without traditional coronary risk factors.50,51 
Protease inhibitor therapy markedly alters lipid metabolism and can be 
associated with premature atherosclerotic disease. Chronic inflammatory 
states have also been associated with atherosclerotic disease. 
Atherosclerotic disease is believed to have multi factorial causes and is 
prone to plaque rupture, possibly related to the host environment.52 
Lipodystrophy should be recognized and treated  because of an elevated 10 
year cardiovascular risk.44,51 Risk stratification based on traditional risk 
factors plus diet, alcohol intake, physical exercise, hypertriglyceridemia, 
cocaine use, heroin use, thyroid disease, renal disease and hypogonadism 
should be considered for long term cardiac preventive care.13,51,53 
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VASCULITIS  
 Most types of vasculitis have been reported in HIV-infected patients. 
Vasculitis should be suspected in patients with fever of unknown origin, 
unexplained multi system disease, arthritis or myositis, glomerulonephritis, 
peripheral neuropathy (especially mononeuritis multiplex) and unexplained 
gastrointestinal, cardiac or central nervous system ischemia. 
Immunomodulatory therapy, chiefly with systemic corticosteroid therapy 
has been successful.14 
AUTONOMIC DYSFUNCTION  
 Early signs of autonomic dysfunction include syncope and 
presyncope, diminished sweating, diarrhea, bladder dysfunction and 
impotence. Patients with HIV - associated nervous system disease have the 
greatest abnormalities in autonomic function.54 
DISORDERS OF RHYTHM 
 Sudden death and rhythm abnormalities are common in HIV 
infection and account for 20% of cardiac related death in this group of 
patients. These can be secondary to other cardiac pathology or be a 
consequence of some forms of treatment like pentamidine induced torsade 
de pointes ventricular tachycardia.8 HIV infection itself is associated with 
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QT prolongation and torsades de pointes ventricular tachycardia.                   
The incidence increases with progression to AIDS.55 
 Hepatitis C is independently associated with increased QT duration and  
co infection with HIV nearly doubles the risk.56 Concomitant electrolyte 
abnormalities can be important in development of cardiac arrhythmia.                    
ECG abnormalities and rhythm disturbances are not uncommon findings in 
HIV positive patients with myocarditis or heart muscle disease and ectopic 
beats, ventricular tachycardia, and sudden death have also been reported.8  
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MATERIALS AND METHODS 
Place of study – Department of Medicine, Kilpauk Medical College and 
Hospital 
Collaborating Department – ART Centre, Department of Cardiology, 
Kilpauk Medical College and Hospital 
Duration of the study – January 2008 to June 2008 
Type of study – Cross sectional study 
STUDY POPULATION 
 A total of 200 patients were randomly chosen at the start of the 
study. Fifty patients were excluded from study because of exclusion 
criteria. Remaining 150 patients were divided into two groups depending 
on the CD4 count. Group I included patients with CD4 count                    
≤ 350 cells / mm3. Group II included patients with CD4 count > 350 cells / 
mm3. Because majority of  the individuals in South Indian populations 
with CD4 counts of 200 - 350 cells / mm3  have high viral road than North 
Indian and Western counter parts,57  an  attempt was made to find out the 
cardiac abnormalities with CD4 count of  350 cells / mm3 as a dividing line 
instead of CD4 count of 200 cells / mm3. 
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INCLUSION CRITERIA 
1. Patients who have been diagnosed as HIV positive by ELISA method 
EXCLUSION CRITERIA 
1. Age less than 18 years and more than 55 years 
2. Treatment with anti-retroviral drugs or any cardiotoxic drugs 
3. Diabetes  
4. Hypertension  
5. Previous congenital or acquired heart disease 
6. Neoplastic diseases 
7. Family history of cardiovascular diseases 
8. Patients having lipid profile abnormalities 
RISK FACTOR ASSESSMENT QUESTIONNAIRE 
 All HIV infected individuals who were included in this study were 
subjected to a questionnaire to assess the risks of acquiring HIV, risk 
factors for cardiac disease and symptomatology of cardiac illness. 
 To assess the risk of acquiring HIV, history regarding their sexual 
exposures, use of intravenous drugs and history of blood transfusion were 
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asked. The individual’s occupation, marital status, extramarital and 
premarital sexual exposures, history of past and present sexually 
transmitted infections were also noted. 
 To assess the risk factors for cardiac disease, questions regarding 
duration and amount of smoking and alcohol consumption were asked. 
 To assess the symptoms of cardiac disease questions regarding 
presence of chest pain, breathlessness, palpitation, pedal edema and fatigue 
were asked. Duration of each symptom was also noted. 
CLINICAL EXAMINATION 
 All patients were meticulously examined for the presence of anemia, 
cyanosis, clubbing, pedal edema, dyspnea, jaundice, generalized 
lymphadenopathy and skin and mucous membrane lesions. Respiratory 
rate, pulse rate, jugular venous pressure, blood pressure (both in supine and 
erect posture) were also recorded. 
 A thorough clinical examination of the cardiovascular system, 
respiratory system, abdomen and central nervous system was done. 
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LABORATORY INVESTIGATIONS 
 All of them were subjected to the following investigations. 
Complete blood count, blood urea and sugar, serum creatinine and 
electrolytes, liver function tests (serum bilirubin, alanine transaminase, 
aspartate transaminase and alkaline phosphatase) and Serum lipid profile 
were done for all patients.  
A standard 12 lead resting electrocardiogram was taken for all individuals 
in this study. 
CD4 Count Assay 
The standard method for enumerating CD4 T cells uses a flow 
cytometer. Computer calculates the number of CD4 T cells by analyzing 
the size of the cell and which of the antibodies it has been tagged with. The 
overall process is called Fluorescence Activated Cell Sorting (FACS). 
IMAGING 
Chest Skiagram 
An erect X-ray of the chest on deep inspiration in the postero-
anterior view was taken for all patients.  
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Echocardiography 
Two dimensional Echocardiography was done for all patients 
included in this study in Department of Cardiology, Kilpauk Medical 
College Hospital, Chennai. 
Statistical analysis 
 Statistical analysis was done by using windows SPSS software 
(version 11.5). Chi square test was applied for significance.  “P” value less 
than 0.05 was considered as significant. 
REFERENCE VALUE USED IN THIS STUDY 
BMI (WHO criteria for Asian population) 58 
Body Mass Index = Weight (kg) / Height in meter 2 
Values        18.5 - 22.9 kg / m2 was taken as normal weight 
  < 18.5 kg / m2 was taken as underweight 
  23- 29.9 kg / m2 was taken as overweight 
  ≥ 30 kg / m2 was taken as obesity  
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CASE SCREENING - FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n - Number 
Cases with HIV positivity screened 
(n=2O0) 
Cases included for study 
(n=150) 
Group I 
CD4 count  
≤ 350/mm3 
(n=51) 
Cases excluded from 
study 
                     ( 50) 
Group II 
CD4 count         
>350 / mm3 
(n=99) 
Diabetes Mellitus   
n=15    
Hypertension          
n=10     
H/O IHD  n=18 
Ab l Li id             
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     RESULTS  
1.  A total of 150 HIV seropositive patients were studied. They were 
divided into two groups.  
2. Group I included 51 HIV seropositive patients with CD4 cell count 
≤ 350 cells / mm3 (n=51). 
3. Group II included 99 HIV seropositive patients, with CD4 count      
> 350 cells / mm3 (n=99). 
4. Mean CD4 count of study population was 473.34 ± 223.20 cells / 
mm3 (Group I - 261.08 ± 83.75 cells / mm3 ; Group II was 582.69 ± 
191.24 cells / mm3).  
5. Out of 150 patients, 62 (41.3%) were males (Group I - 30; Group II 
- 32) and 88 (58.7%) were females (Group I – 21; Group II – 67). 
6. Mean age of study group was 30.87 ± 6.11 years (Group I - 31.43 ± 
6.23 years; Group II - 30.58 ± 6.06 years).  
7. House wives and unskilled labourers constituted the majority of the 
study group about 35% and 34.9% respectively. 
8. Heterosexual route was the most common mode of transmission of 
HIV infection about 95.3%. 
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9. Mean duration of HIV infection was 3.18 years (Group I – 2.95 
years; Group II – 3.3 years ) 
10. Smokers and alcoholics constituted 7.3% (11 patients) and            
8% (12 patients) of the study population respectively. 
11. Mean BMI was 20.40 ± 3.89 kg / m2 (Group I and Group II were 
19.85 ± 4.01 kg / m2 and 20.68 ± 3.82 kg / m2 respectively). 
12. Most patients were asymptomatic. Cardiac symptoms were found in 
10 (6.7%) patients (Group I - 9; Group II – 1). 
13. Twenty three patients (15.3%) (Group I – 15; Group II - 8) were 
found to have opportunistic infections. Oral candidiasis was the 
most common opportunistic infection followed by Tuberculosis and 
Herpes zoster. 
14. Cardiac abnormalities either in the form of Electrocardiography or 
Echocardiography abnormality was found in 25 (16.7%) patients                 
(Group I – 16; Group II – 9). 
15. Twenty two (14.7%) patients had Electrocardiographic 
abnormalities     (Group I – 14; Group II – 8). 
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16. Echocardiography abnormality was seen in 16 (10.7%) patients 
(Group I – 13; Group II – 3). Pericardial effusion was the most 
common abnormality. 
17. Significant correlation was found between CD4 count, duration of 
HIV infection, cardiac symptoms and opportunistic infections with 
cardiac abnormalities.  
18. There was no significant correlation between age, sex, BMI, 
smoking and alcohol with cardiac abnormalities. 
CD4 GROUP 
Table 5 
CD4 
GROUP
NUMBER OF 
PATIENTS
CD4 COUNT 
cells / mm3 
MEAN  CD4 COUNT   
cells / mm3
I 51 ≤ 350 261.08 ±  83.75
II 99 > 350 582.69 ± 191.24
TOTAL 150 473.34 ± 223.20
 
Mean CD4 count in study population was 473.34 ± 223.20cells / mm3. 
Mean CD4 count in Group I was 261.08 ± 83.75 cells / mm3. 
Mean CD4 count in Group II was 582.9 ± 19.24 cells / mm3. 
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CARDIAC ABNORMALITIES 
Table 6 
CARDIAC 
ABNORMALITIES
NUMBER OF 
PATIENTS PERCENTAGE
PRESENT
25 16.70%
ABSENT 
125 83.30%
TOTAL
150 100%
 
Prevalence of cardiac abnormalities either in the form of 
electrocardiography or echocardiography abnormality was 16.7%. 
CD4 GROUP AND CARDIAC ABNORMALITIES 
Table 7 
PRESENT ABSENT
I 16         35               51           
II 9          90               99           
TOTAL 25         125              150          
CD4 GROUP
CARDIAC ABNORMALITIES
TOTAL  
 
   P value was 0.001  statistically significant. 
There was a statistically significant difference observed between CD4 
group and cardiac abnormalities. Prevalence of cardiac abnormalities 
increased with decline in CD4 count (P < 0.05). 
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AGE DISTRIBUTION IN RELATION TO CARDIAC 
ABNORMALITIES AND CD4 COUNT     
Table 8 
CD4 GROUP
MEAN AGE 
(Years)
I 31.43  ± 6.23
II 30.58  ± 6.06
TOTAL 30.87 ± 6.11
 
Mean age in study population was 30.87 ± 6.11 years. 
 Mean age in Group I was 31.43 ± 6.23 years. 
 Mean age in group II was 30.58 ± 6.06 years. 
Table 9 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
20-25 3         (5.9%) 
6        
(11.8%)
9 
(17.6%)
3         
(3.1%)
14  
(14.1%)
17 
(17.2%)
26-30 4         (7.8%)
13  
(25.5%)
17  
(33.3%)
4         
(4.1%)
38      
(38.4%)
42 
(42.4%)
31-35 6         (11.8%)
 8       
(15.7%)
14 
(27.5%)
1         
(1%)
21  
(21.2%)
22     
(22%)
36-40 1         (2%)
7        
(13.7%)
8 
(15.7%)
1         
(1%)
13  
(13.1%)
14  
(14%)
≥ 41 2         (3.9%)
1        
(2%)
3       
(5.9%)
0         
(0%)
4         
(4%)
4       
(4%)
TOTAL 16        (31.4%)
35        
(68.6%)
51 
(100%)
9         
(9.1%)
90  
(90.9%)
99 
(100%)
AGE IN 
YEARS CARDIAC ABNORMALITIES
CD4 GROUP II
CARDIAC ABNORMALITIES
CD4 GROUP I
 
  P value for Group I was 0.352              statistically not significant. 
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P value for Group II was 0.639             statistically not significant. 
There was no statistically significant difference noted between age and 
cardiac abnormalities in both the groups (P > 0.05). 
SEX DISTRIBUTION IN RELATION TO CARDIAC 
ABNORMALITIES AND CD4 COUNT      
Table 10 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
MALE 9          (17.6%)
21       
(41.2%)
30   
(58.8%)
5        
(5.1%)
27  
(27.3%)
32        
(32.3%)
FEMALE 7        (13.7%)
14       
(27.5%)
21   
(41.2%)
4          
(4%)
63       
(63.6%)
67        
(67.7%)
TOTAL 16       (31.4%)
35    
(68.6%)
51    
(100%)
9         
(9.1%)
90       
( 90.9%)
99        
(100%)
SEX 
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.801              statistically not significant. 
  P value for Group II was 0.118             statistically not significant. 
There was no statistically significant difference noted between sex and 
cardiac abnormalities in both the groups (P > 0.05). 
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OCCUPATION 
Table 11 
OCCUPATION TOTAL 
1. Unskilled labourer 52 (34.7%)
2. Skilled labourer 10 (6.67%)
3. Lorry driver 27 (18%)
4. Commercial sex worker 2 (1.3%)
5. Office worker 4 (2.7%)
6. House wife 53 (35.3%)
7. Landlord/ Business man 2 (1.3%)
 
ROUTE OF TRANSMISSION 
Table 12 
ROUTE OF 
TRANSMISSION TOTAL
1. Heterosexual 143 (95.3%)
2. Homosexual 1 (0.7%)
3. Bisexual 1 (0.7%)
4. IV drug users 2 (1.3%)
5. Blood transfusion 2 (1.3%)
6. Unknown 1 (0.7%)
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BMI IN RELATION TO CARDIAC ABNORMALITIES AND CD4 
COUNT   
Table 13 
CD4 GROUP
MEAN BMI   
(kg / m2)
I 19.85 ±  4.01
II 20.68 ±  3.82
TOTAL 20.40 ±  3.89
 
Mean BMI in study population was 20.40 ± 3.89 (kg / m2). 
Mean BMI in Group I was 19.85 ± 4.01 (kg / m2). 
Mean BMI in group II was 20.68 ± 3.82 (kg / m2). 
Table 14 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
NORMAL 7         (13.7%)  
13        
(25.5%)
20 
(39.2%)
6          
(6.1%)
42  
(42.4%)
48       
(48.5%)
OVER 
WEIGHT
2         
(3.9%)
8         
(15.7%)
10 
(19.6%)
1          
(1%)
18  
(18.2%)
19       
(19.2%)
OBESE 0         (0%)
0         
(0%)
0       
(0%)
1          
(1%)
2         
(2%)
3       
(3%)
TOTAL 16        (31.4%)
35        
(68.6%)
51      
(100%)
9          
(9.1%)
90  
(90.9%)
99      
(100%)
UNDER 
WEIGHT
BMI
CD4 GROUP I
7         
(13.7%)
14        
(27.5%)
21       
(41.2%)
1          
(1%)
28        
(28.3%)
29       
(29.3%)
CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.684               statistically not significant. 
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  P value for Group II was 0.234              statistically not significant. 
There was statistically no significant difference noted between BMI and 
cardiac abnormalities in both the Groups (P > 0.05).  
WHO STAGING IN RELATION TO CARDIAC ABNORMALITIES 
AND CD4 COUNT    
Table 15 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
STAGE 1 3         (5.9%)
13        
(25.5%)
16       
(31.4%)
4         
(4%)
55        
(55.6%)
59       
(59.6%)
STAGE 2 3        (5.9%)
12        
(23.5%)
15       
(29.4%)
2         
(2%)
25        
(25.3%)
27       
(27.3%)
STAGE 3 7         (13.7%)
10        
(19.6%)
17       
(33.3%)
3         
(3%)
10        
(10.1%)
13       
(13.1%)
STAGE 4 3         (5.9%)
0         
(0%)
3       
(5.9%)
0         
(0%)
0         
(0%)
0       
(0%)
TOTAL 16        (31.4%)
35        
(68.6%)
51      
(100%)
9         
(9.1%)
90        
(90.9%)
99      
(100%)
WHO 
STAGING
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.024               statistically significant. 
 P value for Group II was 0.169             statistically not significant. 
There was a statistically significant difference noted between WHO 
staging and cardiac abnormalities in Group I (P < 0.05) in contrast to           
Group II (P > 0.05) which was insignificant. 
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DURATION OF HIV INFECTION IN RELATION TO CARDIAC 
ABNORMALITIES AND CD4 COUNT   
Table 16 
CD4 GROUP MEAN DURATION (Years)
I 2.95
II 3.3
TOTAL 3.18  
Mean duration of HIV infection in study population was 3.18 years. 
Mean duration of HIV infection in Group I was 2.95 years.  
Mean duration of HIV infection in Group II was 3.3 years.  
Table 17 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
< 1 year 3         (5.9%)
7         
(13.7%)
10      
(19.%)
1         
(1%)
8         
(8.1%)
9       
(9.1%)
1- 3 years 4         (7.8%)
26        
(51%)
30       
(58.8%)
1         
(1%)
68        
(68.7%)
69      
(9.7%)
>3 years 9         (17.6%)
2         
(3.9%)
11       
(21.6%)
7        
(7.1%)
14        
(14.1%)
21       
(21.2%)
TOTAL 16        (31.4%)
35        
(68.6%)
51      
(100%)
9        
(9.1%)
90        
(90.9%)
99      
(100%)
DURATION 
OF HIV
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.0001          statistically significant. 
           P value for Group II was 0.000           statistically significant. 
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There was a statistically significant increase in cardiac abnormalities 
observed as the duration of HIV infection increases in both the groups     
(P < 0.05). 
SMOKING IN RELATION TO CARDIAC ABNORMALITIES AND 
CD4 COUNT      
Table 18 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
PRESENT 2         (3.9%)
2         
(3.9%)
4       
(7.8%)
0         
(0%)
7         
(7.1%)
7       
(7.1%)
ABSENT 14        (27.5%)
33        
(64.7%)
47       
(92.2%)
9         
(9.1%)
83        
(83.8%)
92       
(92.9%)
TOTAL 16        (31.4%)
35        
(68.6%)
51      
(100%)
9         
(9.1%)
90        
(90.9%)
99      
(100%)
SMOKING
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.403              statistically not significant. 
  P value for Group II was 0.385             statistically not significant. 
There was no statistically significant difference noted between smoking 
and cardiac abnormalities in both the groups (P > 0.05). 
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ALCOHOL IN RELATION TO CARDIAC ABNORMALITIES AND 
CD4 COUNT   
Table 19 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
PRESENT 3         (5.9%)
4        
(7.8%)
7       
(13.7%)
0         
(0%)
5        
(5.1%)
5        
(5.1%)
ABSENT 13        (25.5%)
31     
(60.8%)
44      
(86.3%)
9       
(9.1%)
85       
(85.9%)
94       
(94.9%)
TOTAL 16        (31.4%)
35     
(68.6%)
51      
(100%)
9       
(9.1%)
90       
(90.9%)
99       
(100%)
ALCOHOL
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
 
  P value for Group I was 0.481             statistically not significant. 
  P value for Group II was 0.468            statistically not significant. 
There was no statistically significant difference noted between alcohol and 
cardiac abnormalities in both the groups (P > 0.05). 
CARDIAC SYMPTOMS IN RELATION TO CARDIAC 
ABNORMALITIES AND CD4 COUNT   
Table 20 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
PRESENT
9     
(17.6%)
0        
(0%)
9       
(17.6%)
1          
(1%)
0        
(0%)
1       
(1%)
ABSENT
7          
(13.7%)
35       
(68.6%)
42      
(82.4%)
8          
(8.1%)
90  
(90.9%)
98      
(99%)
TOTAL
16         
(31.4%)
35       
(68.6%)
51      
(100%)
9          
(9.1%)
99       
(90.9%)
99      
(100%)
SYMPTOMS
CD4 GROUP I CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
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 P value for Group I was 0.000             statistically significant. 
P value for Group II was 0.001            statistically significant. 
 A statistically significant correlation was found between cardiac 
symptoms and cardiac abnormalities in both the groups (P < 0.05). 
OPPORTUNISTIC INFECTIONS  
Table 21 
OPPORTUNISTIC  INFECTIONS TOTAL
Absent 127 (84.7%)
Oral Candidiasis 13 (8.7%)
Tuberculosis 6 (4%)
Herpes zoster 4 (2.7%)
Total 150 (100%)
 
OPPORTUNISTIC INFECTIONS IN RELATION TO CARDIAC 
ABNORMALITIES AND CD4 COUNT   
Table 22 
PRESENT ABSENT TOTAL PRESENT ABSENT TOTAL
CD4 GROUP II
CARDIAC ABNORMALITIES CARDIAC ABNORMALITIES
OPPORTUNISTIC 
INFECTIONS
CD4 GROUP I
8         
(15.7%)
7         
(13.7%)
36       
(70.6%)
28        
(54.9%)
8         
(15.7%)ABSENT
PRESENT 15       (29.4%)
9       
(9.1%)
90        
(90.9%)
99       
(100%)
16        
(31.4%)
35        
(68.6%)TOTAL
51       
(100%)
8        
(8.1%)
6        
(6.1%)
2         
(2%)
91       
(91.9%)
84        
(84.8%)
7        
(7.1%)
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  P value for Group I was 0.029             statistically significant. 
  P value for Group II was 0.103            statistically not significant. 
There was a statistically significant correlation noted between 
opportunistic infections and cardiac abnormalities in Group I (P < 0.05) in 
contrast to Group II (P > 0.05) which was insignificant. 
ANALYSIS OF ELECTROCARDIOGRAM:                                                              
 Out of 150 patients 22 patients had ECG abnormalities.  
Table 23 
ECG Abnormalities CD4 Group I
CD4 
Group II TOTAL
Sinus tachycardia 1        (4.54%)
1         
(4.54%)
2        
(9.09%)
Conduction abnormalities - 2 (RBBB)  (9.09%)
2        
(9.09%)
Atrial ectopic 1        (4.54%)
2         
(9.09%)
3        
(13.64%)
Ventricular ectopic 2        (9.09%) -
2        
(9.09%)
Poor progression of R wave 3        (13.64%)
1         
(4.54%)
4        
(18.18%)
Low voltage 5        (22.73%)
1         
(4.54%)
6        
(27.27%)
ST/ T wave abnormality 2        (9.09%)
1         
(4.54%)
3        
(13.64%)
Total 14       (63.64%)
8         
(36.36%)
22       
(100%)  
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ELECTROCARDIOGRAPHIC CHANGES IN RELATION TO CD4 
COUNT   
Table 24 
NORMAL 37            (24.7%)
91             
(60.7%)
128         
(85.3%)
ABNORMAL 14            (9.3%)
8              
(5.3%)
22          
(14.7%)
TOTAL 51            (34%)
99             
(66%)
150         
(100%)
ELECTROCARDIOGRAPHY TOTAL CD4 GROUP I CD4 GROUP II
 
P value was 0.000             statistically significant. 
There was statistically significant difference noted between two groups 
regarding electrocardiographic abnormalities (P < 0.05) . 
Prevalence of electrocardiographic abnormalities increased with decline in 
CD4 count.  
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ECHOCARDIOGRAPHIC FINDINGS:                                                                         
Table 25 
  Sixteen of the 150 patients had ECHO abnormalities. 
Pericardial Effusion 7             
(43.75%)
2              
(12.5%)
9       
(56.25%)
Dilated Cardiomyopathy 4             
(25%)
1              
(6.25%)
5       
(31.25%)
Septal Hypokinesia 1             
(6.25%)
0              
(0%)
1       
(6.25%)
Infective Endocarditis 1             (6.25%)
0              
(0%)
1       
(6.25%)
Total 13            
(81.25%)
3              
(18.75%)
16      
(100%)
CD4 GROUP I CD4 GROUP II TOTALECHOCARDIOGRAPHY
 
ECHOCARDIOGRAPHIC CHANGES IN RELATION TO CD4 
COUNT    
Table 26 
NORMAL 38            (25.3%)
96            
(64%)
134      
(89.3%)
ABNORMAL 13            (8.7%)
3             
(2%)
16       
(10.7%)
TOTAL 51            (34%)
99            
(66%)
150 
(100%)
CD4 GROUP IIECHOCARDIOGRAPHY TOTALCD4 GROUP I
 
           P value was 0.000              statistically significant. 
There was a statistically significant difference noted between two 
groups regarding echocardiographic abnormalities (P < 0.05).Prevalence of 
echocardiographic abnormalities increased with decline in CD4 count.      
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DISCUSSION 
Cardiovascular manifestations of HIV infection have not attracted 
much attention in the Indian sub continent. This is partly because of the 
clinical picture of HIV infection still dominated by opportunistic infections 
and symptoms of  breathlessness, fatigue and poor exercise intolerance are 
frequently ascribed to other conditions associated with HIV infection.    
With the greater access to Anti-retroviral medications more patients may 
live longer enough to present with end organ disorders. Our study throws 
light into various unsuspected cardiac abnormalities in various groups of 
HIV infected patients and its relationship to CD4 count. 
 A study conducted by Kannagai et al57at CMC Vellore in 2008 
has shown that majority of  the HIV infected individuals in South India 
with CD4 counts of 200 - 350 cells / mm3 had higher viral load than that 
suggested by International AIDS Society. 
 Present study was undertaken based on the above observation.         
There are no supportive studies showing the comparison of prevalence               
of cardiac abnormalities with the CD4 counts of ≤ 350 cells/ mm3 and        
> 350 cells / mm3. 
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AGE DISTRIBUTION     
 Our study population consisted of 150 patients. The mean age of our 
study group was 30.87 ± 6.11 years with the age group ranging from 22 to 
50 years. Mean age of Group I and group II were 31.43 ±6.23 years and 
30.58 ± 6.06 years respectively. In a study conducted by Joshi et al at 
Mumbai,59  the age group ranged from 17 to 52 years with the mean age of 
29.8 years. 
 Correlation between age, CD4 count and cardiac abnormalities was 
attempted. In Group I, out of 16 patients with cardiac abnormalities 3 
patients were in 20 - 25 years age group, 4 patients were 26 - 30 years age 
group, 6 patients were in 31 - 35 years age group, one patient was in         
36 - 40 years age group and 2 patients were in more than 40 years of age 
group. In Group II, out of 9 patients with cardiac abnormalities 3 patients 
were in 20 - 25 years age group, 4 patients were in 26 - 30 years age group, 
one patient each in 31 - 35 years and 36 - 40 years of age group. P values 
for Group I and Group II were 0.352 and 0.639 respectively which was 
statistically insignificant. There was no correlation between age and 
cardiac abnormalities in this study similar to the study conducted by 
Caggese et al.60 
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GENDER DISTRIBUTION 
 The gender distribution demonstrated a majority of 58.7 % (88) of 
females compared to 41.3% (62) of males. In a study conducted by       
Joshi et al 59,  male and female ratio was 5.7:1 ( 63 males and 11 females).                    
In P Kannan et al 61  study males were 120 and females were 80.               
In El Hattoui et al 62 study males and females were 88 and 70 respectively. 
 Sex distribution in relation to cardiac abnormalities and CD4 count 
was seen. In Group I, 9 males and 7 females had cardiac abnormalities.     
In Group II, 5 males and 4 females had cardiac abnormalities. P values for 
Group I and Group II were 0.801 and 0.118 respectively which was 
statistically insignificant. So sex did not play a significant role in cardiac 
abnormalities in HIV patients.  
OCCUPATION 
 In our study group, house wives and unskilled labourers constituted 
majority of the population about 35% and 34.9% respectively. Skilled 
labourers were 6.67%, 18% was lorry driver, 2.7% was office workers and 
1.3% was commercial sex worker and business man each. 
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ROUTE OF TRANSMISSION 
 Most of the study population had heterosexual behaviour (95.3%). 
Remaining were homosexual (0.7%), bisexual (0.7%), IV drug users 
(1.3%), blood transfusion related (1.3%) and unknown mode of 
transmission was 0.7%. In a study by Joshi et al, 59 among 74 patients 
58.1% were heterosexuals, 4.05% blood transfusion related, 2.7% IV drug 
users, 1.35% bisexuals and 20.27% had multiple risk factors.  
 WHO STAGING 
 In our study, 50% of patients were in stage 1. Of the remaining 28% 
were in stage 2, 20% in stage 3 and 2% in stage 4. In Group I out of 16 
patients with cardiac abnormalities, 3 patients were in stage 1, 3 patients 
were in stage 2, 7 patients were in stage 3 and 3 patients were in stage 4.    
P value was 0.024, statistically significant. In Group II, among 9 patients 
with cardiac abnormalities, 4 patients were in stage 1, 2 patients were in 
stage 2, 3 patients were in stage 3. P value was 0.169, statistically 
insignificant. 
RISK FACTORS 
 In our study group, 7.3% were smokers and 8% were alcoholic.            
In Group I, 7.8% were smokers. Among 16 patients with cardiac 
abnormalities two patients were smokers. In Group II 7.1% were smokers. 
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All patients with cardiac abnormalities were non smokers. P values for 
both the groups were 0.403 and 0.385 respectively, statistically 
insignificant.  
  In Group I, 13.7% were alcoholics. Among 16 patients with cardiac 
abnormalities 3 were alcoholics. In Group II 5.1% were alcoholics. All 
patients with cardiac abnormalities were non alcoholics. P values for both 
the groups were 0.481 and 0.468, statistically insignificant. In a study by      
Smith CJ et al, 63 among 394 patients 45% were smokers and 7% were 
alcoholics. There was no significant correlation between smoking and 
alcohol with cardiac abnormalities in our study. This finding correlated 
well with the study by Caggese et al.60 
DURATION OF HIV INFECTION 
In this study 66% (99/150) of patients had duration of illness 
between 1 - 3 years. 12.7% (19/150) had less than a year and 21.3% 
(32/150) had duration of  > 3 years. The duration of illness ranged from 3 
months to 9.5 years. Mean duration of illness in study population (150 
patients) was 3.18 years. Mean duration of illness in Group I and Group II 
were 2.95 years and 3.3 years respectively. In a study by P Kannan et al, 61 
the duration of illness ranged from 6 months to 7 years. 
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In Group I, among 16 patients with cardiac abnormalities, 9 patients 
had a duration of  > 3 years, 4 patients had a duration of  1 - 3 years and  3 
patients had a duration of less than a year. P value was 0.00015, 
statistically significant. In Group II, among 9 patients with cardiac 
abnormalities 7 patients had a duration of > 3 years, 1 patient had a 
duration of  1 -3 years and 1 patient had a duration of less than a year.       
P value was 0.000, statistically significant. There was a significant 
correlation between duration of HIV infection and cardiac abnormalities. 
SYMPTOMS 
 Most patients were asymptomatic. Only 10 (16.7%) patients had 
cardiac symptoms (Group I - 9, Group II - 1). Among 25 patients with 
cardiac abnormalities 40% (10 / 25) had symptoms. The symptoms were 
dyspnea (10.7%), fatigue (3%), palpitation (1.3%) and chest pain (0.7%). 
A significant correlation was found between cardiac abnormalities and 
cardiac symptoms. P values for both the groups were 0.000 and 0.001 
respectively. In a study by Cardosa JS et al, 64 7.3% (10 / 137) of patients 
were symptomatic. In a study by Ewig S et al, 65 nine out of 14 patients 
(64%) with cardiac abnormalities had symptoms. 
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BMI 
The mean BMI of our study group was 20.40 ± 3.89 kg / m2.                        
The mean BMI of Group I and Group II were 19.85 ± 4.01 kg / m2 and 
20.68 ± 3.82 kg / m2 respectively.  
 In Group I, out of 16 patients with cardiac abnormalities, 7 were 
underweight, 2 patients were overweight and 7 patients had normal BMI. 
In Group II, out of 9 patients with cardiac abnormalities, 6 patients had 
normal BMI, one patient was underweight, one patient was overweight and 
one patient was obese. P values for Group I and Group II were 0.684 and 
0.234 respectively, statistically insignificant. There was no significant 
correlation between BMI and cardiac abnormalities. 
OPPORTUNISTIC INFECTIONS 
 In our study 23 patients (15.4%) had opportunistic infections.                     
Oral candidiasis was the most common (8.7%) followed by tuberculosis 
(4%) and herpes zoster (2.7%). In Group I, out of 16 patients with cardiac 
abnormalities, 8 patients had opportunistic infections. P value was 0.029, 
statistically significant. In Group II, out of 9 patients with cardiac 
abnormalities, 2 patients had opportunistic infections. P value was 0.103, 
statistically insignificant. So fall in CD4 count proportionally increases the 
predisposition to both opportunistic infections and cardiac abnormalities.   
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In a study by  De castro et al,66  72 patients (63%) had opportunistic 
infections or secondary malignancies. 45.6% had cardiac involvement 
presumably due to opportunistic infections and secondary malignancy.     
In Caggese L et al 60 study, no correlation was found between opportunistic 
infections and cardiac abnormalities. 
ELECTROCARDIOGRAPHIC ABNORMALITIES 
 Electrocardiographic abnormalities were seen in 22 patients 
(14.7%). Nine Patients had ECG abnormalities without echocardiographic 
abnormalities. Three patients had normal ECG inspite of 
echocardiographic abnormality. In Group I, among 51 patients, 14 patients 
had ECG abnormalities.  In Group II, 8 patients had ECG abnormalities. 
The ECG abnormalities observed were low voltage complexes (27.27%), 
poor progression of R wave (18.18%), non specific ST-T changes 
(13.64%), atrial ectopic (13.64%), right bundle branch block (9.09%), 
sinus tachycardia (9.09%) and ventricular ectopic (9.09%).There was a 
significant correlation between CD4 count and ECG abnormalities           
(P value was 0.000).  In a study by Herdy GV et al, 67 out of 50 patients 18 
patients had sinus tachycardia, 10 patients had ST-T changes, 5 patients 
had low voltage complexes, 5 patients had ST segment elevation and 3 
patients had extra systole. In Mirri A et al 68 study, ECG abnormalities 
unrelated to echocardiographic abnormalities or clinical problems were 
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seen in 11 patients. In Joshi et al 59 study, among 74 patients, 20.27% had 
ECG abnormalities. 
ECHOCARDIOGRAPHIC ABNORMALITIES 
 Prevalence of cardiac abnormalities by echocardiography in our 
study was 10.7% (8.7% in Group I and 2% in Group II). 
Echocardiographic findings were pericardial effusion (56.25%), dilated 
cardiomyopathy (31.25%), interventricular septal hypokinesia (6.25%) and 
infective endocarditis (6.25%). Group I revealed 81.25% (13/16) cases and 
Group II revealed 18.75% (3/16) cases with echocardiographic 
abnormalities. P value was 0.000, statistically significant. There was a 
significant correlation CD4 count and echocardiographic abnormalities. In 
a study by Joshi et al,59 among 74 patients 10.6% had dilated 
cardiomyopathy, 8.5% had pericardial effusion, 4.2% had vegetations, 
2.1% had constrictive pericarditis and 10.6% had incidental valvular, left 
ventricular hypertrophy, ischemic heart disease. In a study by            
Mishra et al 69 at AIIMS, 36.7% had diastolic dysfunction and 23.3% had 
systolic dysfunction. In P Kannan et al 61 study, out of 200 patients, 28 
patients had left ventricular dysfunction, 20 patients had pericardial 
effusion, 6 patients had pulmonary hypertension and one patient had 
dilated cardiomyopathy. In Mirri A et al 68 study, 17% had 
echocardiographic abnormalities. 
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CARDIAC ABNORMALITIES 
 In our study among 150 patients, 25 patients (16.7%) had cardiac 
abnormalities either in the form of ECG or Echocardiography abnormality. 
It is observed that 16 patients out of 51 patients (31.4%) in Group I and     
9 patients out of  99 (9.09%) patients in Group II had cardiac 
abnormalities. There was a statistically significant correlation between 
cardiac abnormalities and CD4 count (P value was 0.0001). As the CD4 
count decreases, the cardiac abnormalities increase proportionally. Cardiac 
abnormalities are inversely proportional to CD4 count. This finding 
correlated well with Cardoso JS et al 65 study and Caggese et al 60 study.   
In a study by S Mishra et al 69, there was no correlation between CD4 
count and diastolic dysfunction. 
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SUMMARY 
 The present study aimed at estimating the prevalence of cardiac 
abnormalities in HIV seropositive patients and also to find out its 
correlation with CD4 counts.  With rigid criteria 150 HIV seropositive 
cases were selected. There were 62 males and 88 females in the study 
group. 
 
Prevalence of cardiac abnormalities was 16.7% in our study.  
Pericardial effusion was the most common echocardiographic abnormality. 
Low voltage complex was the most common electrocardiographic 
abnormality. 
 
Cardiac abnormalities were specifically correlated with CD4 counts.                     
In this study 16 out of 51 patients with CD4 counts ≤ 350/mm3 had cardiac 
abnormalities. 9 out of 99 patients with CD4 counts of > 350/mm3 had 
cardiac abnormalities. 
 
Present study recommends screening for cardiac abnormalities in HIV 
patients to identify early cardiac involvement and minimize cardiac 
complications by early intervention. 
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CONCLUSION 
1. The determination of  Incidence and Prevalence of cardiac abnormalities 
in HIV infected individuals using non invasive tests is quite feasible and 
should be done in all patients registering in ART centre. 
2. There was an inverse correlation between CD4 count and cardiac 
abnormalities. Decline in CD4count below 350 cells / mm3 was associated 
with increased incidence of cardiac abnormalities. 
3. There was a significant correlation between duration of HIV infection 
and cardiac abnormalities. Prevalence of cardiac abnormalities was found 
to be more with increase in the duration of HIV infection. 
4. Most of the patients were asymptomatic. A significant correlation was 
found between cardiac symptoms and cardiac abnormalities.  
5. Heterosexual route was the most common route of transmission of HIV. 
6. Oral candidiasis was the most common opportunistic infection.         
There was a significant correlation between opportunistic infections and 
cardiac abnormalities. 
7. There was no significant correlation between age, sex, BMI, smoking 
and alcohol with cardiac abnormalities. 
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LIMITATIONS 
1. The mean duration of the disease in our patients was less. This could be 
responsible for decreased incidence of cardiac abnormalities in our 
patients. 
2. Follow up study was not done. So the incidence of cardiac abnormalities 
in patients with previous normal echocardiography as well as the natural 
history of those who had Cardiac abnormality could not be studied. 
3. Since the critically ill patients were not included in our study the entire 
spectrum of cardiac abnormalities could not be established.  
5. Viral load could not be estimated due to constraints. 
6. Histopathologic studies like pericardial biopsy, endomyocardial biopsy 
and cytological study of pericardial fluid to determine the etiology of 
pericardial effusion and cardiomyopathy were not done.   
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RECOMMENDATIONS 
1.  A baseline Echocardiographic study for all patients with HIV infection 
at first visit to be done. 
2. Echocardiographic follow up should be done to determine the evaluation 
of cardiac abnormalities and their reversibility with or without treatment. 
3. Histopathologic studies like pericardial biopsy, endomyocardial biopsy 
and cytological study of pericardial fluid to be done to determine the 
etiology of pericardial effusion and cardiomyopathy.     
4. Autopsy studies should be performed in patients dying of HIV 
associated illness and this will throw light on exact incidence of cardiac 
abnormalities in HIV infected patients.     
  
 
 
 
 
 
ABBREVIATION 
AIDS   - Acquired Immuno Deficiency Syndrome 
ANC   - Antenatal clinic 
ART   - Anti Retro Viral Therapy 
ATT   - Anti Tuberculous Therapy 
BMI   - Body Mass Index 
CD   - Cluster Differentiation 
CNS   - Central Nervous System 
CVS   - Cardiovascular system 
DM   - Diabetes Mellitus 
DNA   - Deoxyribonucleic acid 
ECG   - Electrocardiography 
Echo   - Echocardiography 
FSW   - Female Sex Worker 
HAART  - Highly Active Anti Retro Viral Therapy 
HIV    - Human Immunodeficiency Virus 
HT   - Hypertension 
IDU   - Intravenous Drug Users 
JVP   - Jugular venous pressure 
LV   - Left Ventricle 
MSM   - Men having sex with men 
NACO   - National AIDS Control Organization 
NACP  - National AIDS Control Programme 
NHL   - Non Hodgkin’s Lymphoma 
OH   - Orthostatic Hypotension 
RNA   - Ribonucleic acid 
RS   - Respiratory system 
STD   - Sexually Transmitted Disease 
WHO   - World Health Organization 
Kg   - Kilo gram 
µL   - Micro Litre 
mm3   - Cubic millimetre 
m2   - Metre square 
>                  - More than 
≥                             - More than or Equal  
≤                             - Less than or Equal 
<                             - Less than 
%                            - Percentage 
±   - Plus or minus 
&   - And 
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PROFORMA 
 
Name      Hospital No:             Serial No: 
Age        
Sex            Height               WHO Stage: 
Occupation              Weight      Education   : 
Address      BMI 
 
 
Marital status  
 
Sexual exposure 
 
Other risk factors 
 
Partners HIV status 
 
Duration of  HIV infection 
 
Age at first sexual exposure 
 
Recent extra marital exposure 
 
Previous STD’s 
 
Present STD’s 
 
Smoking  
 
Alcohol  
 
DM 
 
HT 
 
Previous cardiac illness 
 
H/O ATT 
 
 
PRESENTING COMPLAINTS 
 
Chest pain 
Breathlessness 
Palpitation 
Pedal edema  
Fatigue  
Postural giddiness 
 
EXAMINATION 
 
Pallor 
Jaundice 
Cyanosis  
Clubbing 
Pedal edema 
Lymphadenopathy 
 
BP:   Supine -                             Standing - 
Pulse rate                                    Respiratory Rate                         Temperature 
JVP 
Opportunistic infections 
 
CVS 
RS 
ABDOMEN 
CNS 
 
INVESTIGATIONS 
 
HEMOGRAM                  CD4 count -  
 
Hb% 
Total count 
Differential count          P -     , L -    ,E -    ,M -    ,B -    . 
ESR 
PCV 
Platelet count 
 
 
 
RENAL FUNCTION TEST 
 
Blood urea 
Blood sugar 
Serum creatinine 
Serum electrolytes 
 
LIPID PROFILE    
 
Total Cholesterol    
Triglycerides      
HDL      
LDL      
VLDL      
 
LIVER FUNCTION TEST 
 
Serum Bilirubin  
SGOT 
SGPT 
Sr. Alkaline Phosphatase 
Total Protein 
Albumin 
Globulin 
 
ECG 
 
Chest X ray 
 
Echocardiography 
 
 
 
 
 
 
 
 
